Abstract 271P
Background
Immune checkpoint inhibitors are now considered revolutionary agents in the treatment of various cancers in the upfront and metastatic setting. The low toxicity and improved quality of life seen with these drugs are an added advantage. However, the real world data regarding their toxicities is limited. The currently published Indian data are restricted to isolated case reports. We planned this study of addressing toxicity profile of various Immunotherapy agents among Indian patients.
Methods
This prospective study was conducted at a tertiary care Hospital in Delhi from Aug 2019 till Nov 2021 after ethics approval. All patients included were treated with Nivolumab, Pembrolizumab, Atezolizumab and Durvalumab. All lines of therapy were allowed for enrolment. Immune Related adverse events were recorded for individual agents and therapy continued until progression or unacceptable toxicity. Toxicities were graded according to NCI:CTCAE criteria ver 4.0. Statistical analysis was done with the use of SPSS software ver 21.0.
Results
A total of 53 patients received Nivolumab, Pembrolizumab, Atezolizumab and Durvalumab. Majority of patients were less than 60 years of age (64.15%). ECOG PS was 1 in 66.04% and PS 2 in 32.08%. Carcinoma(Ca) Lung was the most frequent malignancy (n=18) followed by renal cell carcinoma (15.09%), Relapsed/Refractory Hodgkin’s Lymphoma ( 15.09%), Ca Urinary Bladder ( 11.32%), Malignant Melanoma (7.55%), Recurrent /Metastatic Head and neck cancer ( 7.55%), one each patient of Hepatocellular Ca, Ca Oesophagus, Stomach, Endometrium and Rectum.Nivolumab was used in the majority of study population (49.06%) followed by Pembrolizumab (37.74%), Atezolizumab (9.43%) and Durvalumab (3.77%). Majority of agents were used in 2nd line (52.83%) across various malignancies followed by 1st line usage in 22.64%, 3rd line in 11.32%, 4th line in 7.55% and 5th line usage in 5.66%. All grade adverse events were fatigue (73.58%), anaemia (62.26%), pneumonitis (16.98%), rash (11.32%), dyspnoea (9.43%), diarrhoea (9.43%) and hypothyroidism (7.55%) in majority of patients. Hyperglycaemia, pleural effusion, arthritis, arthralgia and infusion reaction comprising 1.89% each. Severe Grade 3 anaemia was seen in 1 patient (1.89%). None of these led to treatment discontinuation. Details of toxicities are depicted in the table. Table: 271P
Distribution of adverse events in total and in each drugs
Variables | Frequency | Percentage | Atezolizumab | Durvalumab | Nivolumab | Pembrolizumab | |
Dermatologic | Rash | 6 | 11.32% | 0 | 0 | 3 | 3 |
Grade (Gd) 1 | 4 | 7.55% | 0 | 0 | 2 | 2 | |
Gd 2 | 2 | 3.77% | 0 | 0 | 1 | 1 | |
Gastroenterology | Diarrhoea | 5 | 9.43% | 1 | 0 | 2 | 2 |
Gd 1 | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Gd 3 | 1 | 1.89% | 0 | 0 | 1 | 0 | |
Endocrine | Hyperglycaemia | 1 | 1.89% | 0 | 1 | 0 | 0 |
Gd 2 | 1 | 1.89% | 0 | 1 | 0 | 0 | |
Hypothyroidism | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Gd 2 | 4 | 7.55% | 1 | 0 | 1 | 2 | |
Respiratory | Dyspnoea | 5 | 9.43% | 1 | 0 | 2 | 2 |
Gd 1 | 5 | 9.43% | 1 | 0 | 2 | 2 | |
Pneumonitis | 9 | 16.98% | 0 | 0 | 4 | 5 | |
Gd 1 | 8 | 15.09% | 0 | 0 | 4 | 4 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Pleural effusion | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Hematologic | Anaemia | 33 | 62.26% | 3 | 1 | 17 | 12 |
Gd 1 | 31 | 58.49% | 3 | 1 | 17 | 10 | |
Gd 2 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Gd 3 | 1 | 1.89% | 0 | 0 | 0 | 1 | |
Infusion related | Gd 1 | 1 | 1.89% | 0 | 0 | 0 | 1 |
General | Fatigue | 39 | 73.58% | 5 | 1 | 17 | 16 |
Gd 1 | 37 | 69.81% | 5 | 1 | 16 | 15 | |
Gd 2 | 2 | 3.77% | 0 | 0 | 1 | 1 |
Conclusions
Overall, the toxicity seen in Indian patients largely comparable with international experiences and Oncologists should feel reassured using these agents in similar settings in India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03